Literature DB >> 17075479

Peritoneal carcinomatosis of colorectal origin.

Dominique Elias1, Bruno Raynard, Ferechte Farkhondeh, Diane Goéré, Delphine Rouquie, Raoul Ciuchendea, Marc Pocard, Michel Ducreux.   

Abstract

PURPOSE: Complete resection of macroscopic colorectal peritoneal carcinomatosis (PC), followed by intraoperative intraperitoneal chemohyperthermia (IPCH) to treat residual microscopic disease achieves cure in some patients. We report long-term results concerning survival of a phase II study using oxaliplatin (LOHP). PATIENTS AND METHODS: From June 1998 to December 2003, thirty patients with macroscopic colorectal PC underwent complete resection of PC followed by IPCH with LOHP performed in an open abdominal cavity. The dose of LOHP was 460 mg/m2 in 2 L/m2 of iso-osmotic 5% dextrose, over 30 min at an intraperitoneally homogenous temperature of 43 degrees C and at a flow rate of 2 L/min in the continuous closed circuit. During the hour preceding IPCH, patients received 5-fluorouracil (400 mg/m2) and leucovorin (20 mg/m2) intravenously. All patients received neoadjuvant and adjuvant systemic chemotherapy.
RESULTS: Mean peritoneal tumor extension (Sugarbaker's Score) was 14.3 +/- 3.8, median operative duration, 450 min, and median blood loss, 940 mL. Eleven (37%) patients had associated extra-peritoneal lesions which were resected during the same procedure. There were no postoperative deaths and grade 2-3 morbidity (requiring specific treatment) was 40%. Median follow-up was 55 months (range: 31-84). Twenty-two patients (73%) relapsed after a median interval of 14 months, but 7 of them (32%) were amenable to curative repeat surgery. At 3 and 5 years, overall survival rates (95% confidence interval) were 53% (9-72), and 48.5% (31-66) respectively. At 3 and 5 years, disease-free survival rates were 41.5% (27-59), and 34% (19-52) respectively. Median survival was 60.1 months.
CONCLUSION: When feasible, this treatment modality yields a 5-year survival rate of 48.5%, with median survival attaining 60.1 months.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17075479     DOI: 10.1016/s0399-8320(06)73512-6

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  21 in total

1.  Cytoreductive surgery and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colonic origin: outcomes after 7 years' experience of a new centre for peritoneal surface malignancies.

Authors:  Pedro Bretcha-Boix; Jose Farré-Alegre; Manuel Sureda; Carlos Dussan; Juan José Pérez Ruixo; Antonio Brugarolas Masllorens
Journal:  Clin Transl Oncol       Date:  2010-06       Impact factor: 3.405

Review 2.  Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.

Authors:  Hassan-Alaa-Hammed Al-Shammaa; Yan Li; Yutaka Yonemura
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

3.  Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms.

Authors:  P Dubé; L Sideris; C Law; L Mack; E Haase; C Giacomantonio; A Govindarajan; M K Krzyzanowska; P Major; Y McConnell; W Temple; R Younan; J A McCart
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

4.  Hepatic necrosis and hemorrhage following hyperthermic intraperitoneal chemotherapy with oxaliplatin: A review of two cases.

Authors:  Mila Bouchereau; Mai-Kim Gervais; Lucas Sideris; Marie-Hélène Loriot; Stéphane P Ahern; Pierre Dubé
Journal:  J Gastrointest Oncol       Date:  2011-06

5.  The integrity of colonic anastomoses following the intraperitoneal administration of oxaliplatin.

Authors:  Konstantinos Blouhos; Manousos-Georgios Pramateftakis; Theodor Tsachalis; Dimitrios Kanellos; Thomas Zaraboukas; Georgios Koliakos; Dimitrios Betsis
Journal:  Int J Colorectal Dis       Date:  2010-03-09       Impact factor: 2.571

6.  Preclinical antitumor activity of a nanoparticulate SN38.

Authors:  Mazin F Al-Kasspooles; Stephen K Williamson; David Henry; Jahna Howell; Fengui Niu; Charles J Decedue; Katherine F Roby
Journal:  Invest New Drugs       Date:  2013-01-09       Impact factor: 3.850

7.  Fluorescence-Guided Surgery in the Combined Treatment of Peritoneal Carcinomatosis from Colorectal Cancer: Preliminary Results and Considerations.

Authors:  Eva Lieto; Annamaria Auricchio; Francesca Cardella; Andrea Mabilia; Nicoletta Basile; Paolo Castellano; Michele Orditura; Gennaro Galizia
Journal:  World J Surg       Date:  2018-04       Impact factor: 3.352

8.  [Peritoneal carcinomatosis. Surgical treatment, including hyperthermal intraperitoneal chemotherapy].

Authors:  G Glockzin; N Ghali; S A Lang; A Agha; H J Schlitt; P Piso
Journal:  Chirurg       Date:  2007-12       Impact factor: 0.955

9.  [Peritoneal carcinomatosis of colorectal origin: results of cytoreductive surgery with peritonectomy and hyperthermic intraoperative chemotherapy].

Authors:  T Weber; M Roitman; K H Link
Journal:  Chirurg       Date:  2013-02       Impact factor: 0.955

10.  Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases.

Authors:  Robert T Ripley; Jeremy L Davis; Clinton D Kemp; Seth M Steinberg; Mary Ann Toomey; Itzhak Avital
Journal:  Trials       Date:  2010-05-25       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.